Bionano Genomics, Inc. Appoints Alka Chaubey as Chief Medical Officer, Effective August 31, 2020
August 18, 2020 at 08:00 am EDT
Share
Bionano Genomics, Inc. announced that Dr. Alka Chaubey, PhD, FACMG, will join Bionano as its first Chief Medical Officer, effective August 31, 2020. Dr. Chaubey is well known throughout the molecular diagnostics and cytogenetics communities for her contributions to innovation directed toward improving patient outcomes by making the clinical testing process more efficient and more effective. Dr. Chaubey comes to Bionano with almost 20 years of scientific and clinical experience, including at PerkinElmer, where she currently serves as the Head of Cytogenomics for PerkinElmer Genomics and for Vanadis. She holds an academic appointment as the Scientific Director of the Georgia Esoteric and Molecular Laboratory, Scientific Director of the Cytogenetics Laboratory of the Augusta University Medical Center and Adjunct Assistant Professor of Pathology of the Medical College of Georgia at Augusta University.
Bionano Genomics, Inc. is a genomics company. The Company offers optical genome mapping (OGM) solutions for applications across basic, translational and clinical research. Through Lineagen, Inc., the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. It also offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants, and absence of heterozygosity across the genome in one consolidated view. The Company additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. The Company markets and sells OGM systems, including the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation (SV).